Access Vascular and Medline Enter Multi-Year Agreement to Launch Cobranded Next-Generation Vascular Access Catheters
Hospitals across the United States gain access to clinically differentiated midline and PICC catheters designed to combat thrombosis and infection
Access Vascular, Inc. (“AVI”), a medical device company specializing in developing advanced vascular access solutions, and Medline, the largest provider of medical-surgical products and supply chain solutions serving all points of care, today announced a multi-year agreement to accelerate the rollout of AVI’s next-generation catheters, HydroMID® and HydroPICC®, which recently received an anti-thrombogenic indication from the FDA. The initiative bolsters Medline’s existing deep portfolio in vascular access, while leveraging its substantial acute care market presence and clinical expertise in infection prevention and ability to deliver industry leading customized kitting solutions.
Millions of PICC and midline catheters are placed annually in acute care settings, supporting a market of over $600 million. However, the category continues to be anchored in established polyurethane-based catheter technologies, with limited recent innovation. AVI’s HydroMID® and HydroPICC® catheters feature a proprietary hydrogel material with anti-thrombogenic properties to help address catheter-related complications such as thrombosis and occlusion– potential sources of morbidity, readmissions, and cost for health systems*. Addressing these challenges head-on positions AVI and Medline to meet a currently underserved need for providers.
